HKG:6160

5 stories mentioning HKG:6160Updated 30d ago

Every FINWIRES story that references HKG:6160, newest first.

BeOne Reports Positive Interim Results of Mantle Cell Lymphoma Drug Trial; Shares Down 3%

BeOne Medicines (SHA:688235, HKG:6160) said interim results were positive for the Phase Three MANGROVE trial evaluating Brukinsa (zanubrutinib) plus rituximab as first-line treatment for mantle cell lymphoma.The chemotherapy-free regimen reduced disease progression or death risk by 43% versus bendamustine-rituximab, meeting its primary endpoint, according to a Wednesday filing with the Shanghai bourse.BeOne Medicines plans to present full results at a medical congress and pursue global regulatory submissions in late 2026.Shares of the oncology company were down 3% on the Shanghai bourse.

HKG:6160SHA:688235

Asia35d ago

BeOne Medicines Unit to Pay Additional Income Tax

A Chinese unit of BeOne Medicines (SHA:688235, HKG:6160) will pay income tax of 446 million yuan, including late payment surcharges, after receiving a notice from a local tax authority.The company agreed to modify previously filed tax returns as part of the move, according to a Friday Hong Kong bourse filing.No administrative penalty is involved in this tax matter.

HKG:6160SHA:688235

Asia64d ago

Market Chatter: China Approves 15 Domestic Innovative Drugs

Domestic biopharmaceutical developers captured nearly 80% of China's recent innovative drug clearances, marking a major milestone as local pipelines outpace imports.Fifteen of the 19 innovative drugs cleared by the National Medical Products Administration as of May 21 came from domestic companies, The South China Morning Post reported Wednesday.The regulator has overhauled its approval process specifically to fast-track home-grown innovative drugs to market, according to the report.Among those approved was BeOne Medicines' (SHA:688235, HKG:6160) sonrotoclax, used for treating adult blood cancers, the SCMP wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Shanghai Composite^SZSEHKG:6160SHA:688235

Asia78d ago

US Grants Accelerated Approval to BeOne Medicines' Blood Cancer Treatment Beqalzi

BeOne Medicines (SHA:688235, HKG:6160) said the U.S. Food and Drug Administration granted accelerated approval to Beqalzi to treat a type of rare blood cancer, according to a Thursday filing with the Hong Kong bourse.The drug, also known as sonrotoclax, will be available for adult patients with relapsed or refractory mantle cell lymphoma who have failed at least two lines of system therapy.Continued approval for this indication will remain contingent upon confirmation of clinical benefit in the ongoing trial of the medicine.Beqalzi holds the breakthrough therapy, fast-track, and orphan drug designations in this indication, BeOne said.Shares of the company were up over 2% in pre-market trade.

HKG:6160SHA:688235

Asia86d ago

BeOne Medicines' Net Income Soars in Q1; Revenue Up

BeOne Medicines (SHA:688235, HKG:6160) recorded a first-quarter net income surge as revenue grew year over year.GAAP net income was $227.4 million in the first quarter, up from $1.3 million a year prior. GAAP earnings per American depository share increased to $1.96 from $0.01, according to a Wednesday Hong Kong bourse filing.The oncology company's total revenue jumped to $1.51 billion from $1.12 billion over the period.

HKG:6160SHA:688235

Track with the FINWIRES app suite

FolioX

Track HKG:6160 in your portfolio

WheelAI

Analyze HKG:6160 options with the wheel strategy

StockInsider

See market sentiment on HKG:6160